Sleep apnea drug developer Apnimed, backed by Shionogi, is reportedly preparing a U.S. listing to raise as much as $160 million.
Apnimed, a sleep apnea drug developer backed by Shionogi, is reportedly seeking to raise up to $160 million through an initial public offering in the United States. The planned IPO would give investors exposure to a biotech company focused on sleep apnea treatments, a market where clinical progress and funding access are closely watched.